Combined therapy with CD4 + CD25highCD127 - T regulatory cells and anti-CD20 antibody in recent-onset type 1 diabetes is superior to monotherapy: Randomized phase I/II trial.
Maciej ZielińskiMagdalena ŻalińskaDorota Iwaszkiewicz-GrześMateusz GliwińskiMatylda HennigAnna Jaźwińska-CuryłłoHalla KamińskaJustyna SakowskaAnna Wołoszyn-DurkiewiczRadosław OwczukWojciech MłynarskiPrzemysława Jarosz-ChobotArtur BossowskiAgnieszka SzadkowskaJanusz SiebertMałgorzata MyśliwiecNatalia Marek-TrzonkowskaPiotr TrzonkowskiPublished in: Diabetes, obesity & metabolism (2022)
Over 2 years, combined therapy with Tregs and rituximab was consistently superior to monotherapy in delaying T1DM progression in terms of C-peptide levels and the maintenance of remission.
Keyphrases
- open label
- type diabetes
- phase iii
- phase ii
- induced apoptosis
- combination therapy
- clinical trial
- glycemic control
- cell cycle arrest
- study protocol
- cardiovascular disease
- stem cells
- transcription factor
- metabolic syndrome
- oxidative stress
- mesenchymal stem cells
- cell death
- signaling pathway
- cell proliferation
- adipose tissue
- hodgkin lymphoma
- weight loss